



Chloroform

From Wikipedia, the free encyclopedia

Jump to: [navigation](#), [search](#)

Chloroform



[IUPAC name](#)[\[hide\]](#)

Chloroform

[Systematic name](#)[\[hide\]](#)

Trichloromethane

Other names[\[hide\]](#)

Formyl trichloride, Methane trichloride, Methyl trichloride, Methenyl trichloride, TCM, Freon 20, R-20, UN 1888

Identifiers

CAS number	67-66-3 ✓
PubChem	6212
ChemSpider	5977 ✓
UNII	7V31YC746X ✓
EC number	200-663-8
KEGG	C13827 ✓
ChEBI	CHEBI:35255
ChEMBL	ChEMBL44618 ✓
RTECS number	FS9100000

[SMILES](#)

[\[show\]](#)

[InChI](#)

[\[show\]](#)

Properties

Molecular formula	CHCl ₃
Molar mass	119.38 g/mol
Appearance	Colorless liquid
Density	1.483 g/cm ³
Melting point	-63.5 °C
Boiling point	61.2 °C
Solubility in water	0.8 g/100 ml (20 °C)
Refractive index (<i>n</i> _D)	1.4459

Structure

Molecular shape	Tetrahedral
---------------------------------	-------------

Hazards

MSDS	External MSDS
R-phrases	R22, R38, R40, R48/20/22
S-phrases	(S2), S36/37



[NFPA 704](#)

0
2
0

[Flash point](#)

Non-flammable

[U.S. Permissible exposure limit \(PEL\)](#)

50 ppm (240 mg/m³) (OSHA)

[Supplementary data page](#)

[Structure and properties](#)

[n](#), [ε](#), etc.

[Thermodynamic data](#)

Phase behaviour
Solid, liquid, gas

[Spectral data](#)

[UV](#), [IR](#), [NMR](#), [MS](#)



[\(what is this?\)](#) [\(verify\)](#)

Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)

[Infobox references](#)



Chloroform in its liquid state shown in a test tube

Chloroform is the [organic compound](#) with [formula](#) CHCl3. The colorless, sweet-smelling, dense liquid is a [trihalomethane](#), and is considered somewhat hazardous. Several million tons are produced annually as a precursor to [Teflon](#) and refrigerants, but its use for refrigerants is being phased out.^{[\[1\]](#)}

Contents

[\[hide\]](#)

- [1 Occurrence](#)
 - [1.1 Marine](#)
- [2 Production](#)
 - [2.1 Industrial routes](#)
 - [2.2 Deuteriochloroform](#)
 - [2.3 Inadvertent formation of chloroform](#)

- [3 Uses](#)
 - [3.1 As a solvent](#)
 - [3.2 As a reagent in organic synthesis](#)
 - [3.3 As an anesthetic](#)
 - [3.4 Veterinary use](#)
- [4 Safety](#)
 - [4.1 Conversion to phosgene](#)
- [5 References](#)
- [6 External links](#)

Occurrence

CHCl₃ has a multitude of natural sources, both biogenic and abiotic. It is estimated that greater than 90% of atmospheric CHCl₃ is of natural origin.^[2]

Marine




In particular, chloroform is produced by brown seaweeds (*Laminaria digitata*, *Laminaria saccharina*, *Fucus serratus*, *Pelvetia canaliculata*, *Ascophyllum nodosum*), red seaweeds (*Gigartina stellata*, *Corallina officinalis*, *Polysiphonia lanosa*), and green seaweeds (*Ulva lactuca*, *Enteromorpha* sp., *Cladophora albida*).^[3] Similarly, the macroalga *Eucheuma denticulatum*, which is cultivated and harvested on a large scale for [carrageenan](#) production, produces CHCl₃,^[4] as do *Hypnea spinella*, *Falkenbergia hillebrandii*, and *Gracilaria cornea* along with seven indigenous macroalgae inhabiting a rock pool.^[5] These studies show increased CHCl₃ production with increased light intensity, presumably when photosynthesis is at a maximum. Chloroform is also produced by the brown alga *Fucus vesiculosus*, the green algae *Cladophora glomerata*, *Enteromorpha ahlneriana*, *Enteromorpha flexuosa*, and *Enteromorpha intestinalis*, and the diatom *Pleurosira laevis*.^[6] Other studies observe CHCl₃ in *Fucus serratus*, *Fucus vesiculosus*, *Corallina officinalis*, *Cladophora pellucida*, and *Ulva lactuca*,^[7] and *Desmarestia antarctica*, *Lambia antarctica*, *Laminaria saccharina*, *Neuroglossum ligulatum*.^[8]

Production


Chloroform was discovered by three researchers independently of one another. Chloroform was reported in 1831 by the French [chemist Eugène Soubeiran](#), who prepared it from [acetone](#) (2-propanone) as well as [ethanol](#) through the action of chlorine [bleach](#) powder ([calcium hypochlorite](#)).^[9] The American physician [Samuel Guthrie](#) prepared gallons of the material and described its "deliciousness of flavor."^[10] Independently, [Justus von Liebig](#) also described the same compound.^[11] All early preparations used variations of the [haloform reaction](#). Chloroform was named and chemically characterized in 1834 by [Jean-Baptiste Dumas](#).^[12]

Industrial routes

In industry, chloroform is produced by heating a mixture of [chlorine](#) and either [chloromethane](#) or [methane](#).^[1] At 400–500 °C, a [free radical halogenation](#) occurs, converting these precursors to progressively more chlorinated compounds:



Chloroform undergoes further chlorination to give [CCl₄](#):



The output of this process is a mixture of the four chloromethanes, chloromethane, dichloromethane, chloroform, and carbon tetrachloride, which are then separated by [distillation](#).^[1]

Deuterochloroform


An archaic industrial route to chloroform involved the reaction of acetone (or ethanol) with [sodium hypochlorite](#) or calcium hypochlorite, the aforementioned [haloform reaction](#).^[1] The chloroform can be removed from the coproducts by distillation. A related reaction is still used in the production of [bromoform](#) and [iodoform](#). Although the haloform process is obsolete for the production of ordinary chloroform, it is used to produce CDCl₃.^[citation needed] Deuterochloroform can also be prepared by the reaction of sodium deuterioxide with [chloral hydrate](#),^[citation needed] or from ordinary chloroform.^[13]

Inadvertent formation of chloroform

The haloform reaction can also occur inadvertently in domestic settings. Sodium hypochlorite solution ([chlorine bleach](#)) mixed with common household liquids such as [acetone](#), [butanone](#), [ethanol](#), or [isopropyl alcohol](#) can produce some chloroform, in addition to other compounds such as [chloroacetone](#), or dichloroacetone.

Uses

The major use of chloroform today is in the production of the [chlorodifluoromethane](#) (R-22), a major precursor to [tetrafluoroethylene](#):



The reaction is conducted in the presence of a catalytic amount of [antimony pentafluoride](#).

Chlorodifluoromethane is then converted into tetrafluoroethylene, the main precursor to [Teflon](#). Before the [Montreal Protocol](#), chlorodifluoromethane (R22) was also a popular refrigerant.

As a solvent

Chloroform is a common solvent in the laboratory because it is relatively unreactive, miscible with most organic liquids, and conveniently volatile. Chloroform is used as a [solvent](#) in the [pharmaceutical](#) industry and for producing [dyes](#) and [pesticides](#). Chloroform is an effective solvent for [alkaloids](#) in their base form and thus plant material is commonly extracted with chloroform for pharmaceutical processing. For example, it is used in commerce to extract [morphine](#) from [poppies](#) and [scopolamine](#) from *Datura* plants. Chloroform containing [deuterium](#) (heavy hydrogen), CDCl_3 , is a common solvent used in [NMR spectroscopy](#). It can be used to bond pieces of [acrylic glass](#) (also known under the trade names Perspex and Plexiglas). A solvent of phenol:chloroform:isoamyl alcohol 25:24:1 is used to dissolve non-nucleic acid biomolecules in DNA and RNA extractions.

As a reagent in organic synthesis

As a [reagent](#), chloroform serves as a source of the dichlorocarbene CCl_2 group.^[14] It reacts with aqueous [sodium hydroxide](#) usually in the presence of a [phase transfer catalyst](#) to produce [dichlorocarbene](#), CCl_2 .^{[15][16]} This reagent affects ortho-formylation of activated [aromatic rings](#) such as [phenols](#), producing aryl [aldehydes](#) in a reaction known as the [Reimer-Tiemann reaction](#). Alternatively the [carbene](#) can be trapped by an [alkene](#) to form a [cyclopropane](#) derivative. In the [Kharasch addition](#) chloroform forms the CHCl_2 free radical in addition to alkenes.

As an anesthetic



Antique bottles of Chloroform

Chloroform was once a popular [anesthetic](#); its vapor depresses the [central nervous system](#) of a patient, allowing a doctor to perform various otherwise painful procedures. In 1847, the Scottish [obstetrician James Young Simpson](#) first used chloroform for [general anesthesia](#) during [childbirth](#). The use of chloroform during [surgery](#) expanded rapidly thereafter in Europe. In the United States, chloroform began to replace [ether](#) as an anesthetic at the beginning of the 20th century; however, it was quickly abandoned in favor of ether upon discovery of its toxicity, especially its tendency to cause fatal [cardiac arrhythmia](#) analogous to what is now termed "[sudden sniffer's death](#)". Ether is still the preferred anesthetic in some [developing nations](#) due to its high [therapeutic index](#) (~1.5–2.2)^[17] and low price. One possible mechanism of action for chloroform is that it increases movement of potassium ions through certain types of [potassium channels](#) in

[nerve cells](#).^[18] Chloroform could also be mixed with other anaesthetic agents such as ether to make C.E. mixture, or ether and [alcohol](#) to make [A.C.E. mixture](#).

Veterinary use

In veterinary medicine it is used externally to kill maggots in wounds.^[citation needed]

Safety

Fatal oral dose of chloroform may be as low as 10 mL (14.8 g), with death due to respiratory or cardiac arrest.^[19]

As might be expected for an [anesthetic](#), chloroform vapors depress the [central nervous system](#). It is [immediately dangerous to life and health](#) at approximately 500 [ppm](#), according to the [U.S. National Institute for Occupational Safety and Health](#). Breathing about 900 ppm for a short time can cause dizziness, fatigue, and headache. Chronic chloroform exposure can damage the [liver](#) (where chloroform is metabolized to [phosgene](#)) and to the [kidneys](#), and some people develop sores when the skin is immersed in chloroform.

[Animal studies](#) have shown that [miscarriages](#) occur in [rats](#) and [mice](#) that have breathed [air](#) containing 30 to 300 [ppm](#) of chloroform during [pregnancy](#) and also in rats that have ingested chloroform during pregnancy. [Offspring](#) of rats and mice that breathed chloroform during pregnancy have a higher incidence of [birth defects](#), and abnormal [sperm](#) have been found in male mice that have breathed air containing 400 ppm chloroform for a few days. The effect of chloroform on [reproduction](#) in humans is unknown.

Chloroform once appeared in [toothpastes](#), [cough syrups](#), [ointments](#), and other [pharmaceuticals](#), but it has been banned as a [consumer product](#) in the US since 1976.^[20] Cough syrups containing Chloroform can still be legally purchased in pharmacies and supermarkets in the UK.

The US National Toxicology Program's eleventh report on carcinogens^[21] implicates it as reasonably anticipated to be a human [carcinogen](#), a designation equivalent to [International Agency for Research on Cancer](#) class 2A. The IARC itself classifies chloroform as *possibly carcinogenic to humans*, a Group 2B designation.^[22] It has been most readily associated with [hepatocellular carcinoma](#).^{[23][24]} Caution is mandated during its handling in order to minimize unnecessary exposure; safer alternatives, such as [dichloromethane](#), have resulted in a substantial reduction of its use as a solvent.

Conversion to phosgene

During prolonged storage in the presence of [oxygen](#) chloroform converts slowly to [phosgene](#). To prevent accidents, commercial chloroform is stabilized with [ethanol](#) or [amylene](#), but samples that have been recovered or dried no longer contain any stabilizer. Amylene has been found ineffective, and the phosgene can affect analytes in samples, lipids and nucleic acids dissolved in or extracted with chloroform.^[25]

Dissolved phosgene cannot be removed by distillation or carbon filters, but is removed by calcium hydroxide or activated alumina.^[26] Suspicious samples can be tested for phosgene using filter paper (treated with 5% diphenylamine, 5% dimethylaminobenzaldehyde in alcohol, and then dried), which turns yellow in phosgene vapor. There are several colorimetric and fluorometric reagents for phosgene, and it can also be quantified with mass spectrometry.

References

- ^a ^b ^c ^d M. Rossberg *et al.* "Chlorinated Hydrocarbons" in Ullmann's Encyclopedia of Industrial Chemistry, 2006, Wiley-VCH, Weinheim. doi:10.1002/14356007.a06_233.pub2
- [^] <http://www.eurochlor.org/upload/documents/document56.pdf>
- [^] Nightingale PB, Malin G, Liss PS (1995). "[Production of Chloroform and Other Low-Molecular-Weight Halocarbons by Some Species of Macroalgae](#)". *Limnology and Oceanography* (American Society of Limnology and Oceanography) **40** (4): 680. <http://www.jstor.org/pss/2838303>.
- [^] Mtolera, Matern; Collén, Jonas; Pedersén, Marianne; Ekdahl, Anja; Abrahamsson, Katarina; Semesi, Adelaida (1996). "Stress-induced production of volatile halogenated organic compounds in *Eucheuma denticulatum* (Rhodophyta) caused by elevated pH and high light intensities". *European Journal of Phycology* **31** (1): 89. doi:10.1080/096702696000651241.
- [^] Ekdahl A, Pedersen M, Abrahamsson K (1998). "A Study of the Diurnal Variation of Biogenic Volatile Halocarbons". *Mar Chem* **63**: 1.

6. [^](#) Abrahamsson, K; Choo, KS; Pedersén, M; Johansson, G; Snoeijs, P (2003). "Effects of temperature on the production of hydrogen peroxide and volatile halocarbons by brackish-water algae.". *Phytochemistry* **64** (3): 725–34. doi:[10.1016/S0031-9422\(03\)00419-9](https://doi.org/10.1016/S0031-9422(03)00419-9). PMID [13679095](https://pubmed.ncbi.nlm.nih.gov/13679095/).
7. [^](#) Baker JM, Sturges WT, Sugier J, Sunnenberg G, Lovett AA, Reeves CE, Nightingale PD, Penkett SA (2001). "Emissions of CH₃Br, Organochlorines, and Organiodines from Temperate Macroalgae". *Chemosphere - Global Change Science* **3** (1): 93. doi:[10.1016/S1465-9972\(00\)00021-0](https://doi.org/10.1016/S1465-9972(00)00021-0).
8. [^](#) Laturmus, F; Svensson, T; Wiencke, C; Oberg, G (2004). "Ultraviolet radiation affects emission of ozone-depleting substances by marine macroalgae: results from a laboratory incubation study.". *Environmental science & technology* **38** (24): 6605–9. doi:[10.1021/es049527s](https://doi.org/10.1021/es049527s). PMID [15669318](https://pubmed.ncbi.nlm.nih.gov/15669318/).
9. [^](#) [Eugène Soubeiran](#) (1831). *Ann. Chim.* **48**: 131.
10. [^](#) [Samuel Guthrie](#) (1832). "New mode of preparing a spirituous solution of Chloric Ether". *Am. J. Sci. And Arts* **21**: 64.
11. [^](#) [Justus Liebig](#) (1832). "Ueber die Verbindungen, welche durch die Einwirkung des Chlors auf Alkohol, Aether, ölbildendes Gas und Essiggeist entstehen". *Annalen der Pharmacie* **1** (2): 182–230. doi:[10.1002/jlac.18320010203](https://doi.org/10.1002/jlac.18320010203).
12. [^](#) [Jean-Baptiste Dumas](#) (1834). "Untersuchung über die Wirkung des Chlors auf den Alkohol". *Annalen der Pharmacie* **107** (41): 650–656. doi:[10.1002/andp.18341074103](https://doi.org/10.1002/andp.18341074103).
13. [^](#) [Canadian Patent 1085423](#)
14. [^](#) [Srebnik, M.; Laloë, E.](#) "Chloroform" *Encyclopedia of Reagents for Organic Synthesis* 2001 John Wiley. doi:[10.1002/047084289X.rc105](https://doi.org/10.1002/047084289X.rc105)
15. [^](#) ["1,6-Methanof\[10\]annulene"](#), *Org. Synth.*, 1988, <http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?prep=cv6p0731>; *Coll. Vol. 6*: 731
16. [^](#) [Gokel, G. W.; Widera, R. P.; Weber, W. P.](#) (1988), ["Phase-Transfer Hofmann Carbylamine Reaction: tert-Butyl Isocyanide"](#), *Org. Synth.*, <http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?prep=cv6p0232>; *Coll. Vol. 6*: 232
17. [^](#) [Calderone, F.A.](#) (1935). *J. Pharmacology Experimental Therapeutics* **55**: 24. <http://jpet.aspetjournals.org/cgi/reprint/55/1/24.pdf>.
18. [^](#) [Patel, Amanda J.; Honoré, Eric; Lesage, Florian; Fink, Michel; Romey, Georges; Lazdunski, Michel](#) (May 1999). "Inhalational anesthetics activate two-pore-domain background K⁺ channels". *Nature Neuroscience* **2** (5): 422–426. doi:[10.1038/8084](https://doi.org/10.1038/8084). PMID [10321245](https://pubmed.ncbi.nlm.nih.gov/10321245/).
19. [^](#) [Chloroform](#), US Environmental Protection Agency
20. [^](#) ["The National Toxicology Program: Substance Profiles: Chloroform CAS No. 67-66-3"](#) (pdf). <http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s038chlo.pdf>. Retrieved 2007-11-02.
21. [^](#) ["11th Report on Carcinogens"](#). <http://ntp.niehs.nih.gov/ntp/roc/toc11.html>. Retrieved 2007-11-02.
22. [^](#) ["International Agency for Research on Cancer \(IARC\) - Summaries & Evaluations: Chloroform"](#). <http://www.inchem.org/documents/iarc/vol73/73-05.html>. Retrieved 2010-09-02.
23. [^](#) ["Centers for Disease Control and Prevention: Current Intelligence Bulletin 9"](#). http://www.cdc.gov/Niosh/78127_9.html.
24. [^](#) ["National Toxicology Program: Report on the carcinogenesis bioassay of chloroform"](#). http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/trChloroform.pdf.
25. [^](#) [\(Turk, Eric,](#) "Phosgene from Chloroform", *Chemical & Engineering News* (2 March 1998) Vol. 76, No. 9, pp. 6.)
26. [^](#) [\(Cone, Edward J., William F. Buckwald, and William D. Darwin,](#) "Analytical controls in Drug Metabolic Studies, II Artifact formation During Chloroform Extraction of Drugs and Metabolites with Amine Substituents", *Drug Metabolism & Disposition* November 1982 vol. 10 no. 6 561-567)

External links

- [Chloroform "The Molecular Lifesaver"](#) An article at Oxford University providing facts about chloroform.
- [Concise International Chemical Assessment Document 58](#)
- [History of chloroform anesthesia](#)
- IARC Summaries & Evaluations: [Vol. 1 \(1972\)](#), [Vol. 20 \(1979\)](#), [Suppl. 7 \(1987\)](#), [Vol. 73 \(1999\)](#)



- [International Chemical Safety Card 0027](#)
- [NIOSH Pocket Guide to Chemical Hazards 0127](#)
- [National Pollutant Inventory - Chloroform and trichloromethane](#)
- [NIST Standard Reference Database](#)
- [Story on Chloroform](#) from BBC's The Material World (28 July 2005)
- [Sudden Sniffer's Death Syndrome](#) article at Carolina Poison Center
- Calculation of [vapor pressure](#), [liquid density](#), [dynamic liquid viscosity](#), [surface tension](#) of chloroform
- [ChemSub Online: Chloroform - Methane, trichloro-](#)

Fentanyl

From Wikipedia, the free encyclopedia

Jump to: [navigation](#), [search](#)

Fentanyl



Systematic (IUPAC) name

N-(1-(2-phenylethyl)-4-piperidinyl)-*N*-phenylpropanamide

Identifiers

CAS number [437-38-7](#)

ATC code [N01AH01](#) [N02AB03](#)

PubChem [CID 3345](#)

IUPHAR ligand [1626](#)

DrugBank [DB00813](#)

ChemSpider [3228](#) 

[UNII](#) [UF599785JZ](#) ✓

[KEGG](#) [D00320](#) ✓

[ChEMBL](#) [CHEMBL596](#) ✓

Chemical data

[Formula](#) $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O}$

[Mol. mass](#) 336.471 g/mol

[SMILES](#) [eMolecules](#) & [PubChem](#)

[InChI\[show\]](#)

Physical data

[Melt. point](#) 87.5 °C (190 °F)

Pharmacokinetic data

[Bioavailability](#) 92% (transdermal)
89% (intranasal)
50% (buccal)
33% (ingestion)

[Protein binding](#) 80-85%

[Metabolism](#) [hepatic](#), primarily by [CYP3A4](#)

(IV)= 2.5 minutes

[Half-life](#) Intranasal = 6.5 mins

Transdermal = 7 hours (range 3–12 h)

[Excretion](#) 60% Urinary (metabolites, <10% unchanged drug)^[1]

Therapeutic considerations

[Pregnancy cat.](#) C(US)

[Legal status](#) ? (UK) [Schedule II](#) (US)

[Dependence liability](#) Moderate - High

[Routes](#) [TD](#), [IM](#), [IV](#), oral, [sublingual](#), [buccal](#)

✓ [\(what is this?\)](#) [\(verify\)](#)

Fentanyl (also known as **fentanil**, brand names Sublimaze,^[2] [Actiq](#), [Durogesic](#), [Duragesic](#), Fentora, Onsolis,^[3] [Instanyl](#),^[4] [Abstral](#),^[5] and others) is a potent synthetic [narcotic analgesic](#) with a rapid onset and short duration of action.^[6] It is a strong agonist at the [μ-opioid](#) receptors. Historically it has been used to treat [chronic breakthrough pain](#) and is commonly used before procedures as an [anesthetic](#) in combination with a [benzodiazepine](#).^[7]

Fentanyl is approximately 80 times more potent than [morphine](#),^[8] with 100 micrograms of fentanyl approximately equivalent to 10 mg of morphine and 75 mg of [pethidine](#) (meperidine) in analgesic activity.^[8] It has an [LD₅₀](#) of 3.1 milligrams per kilogram in rats, and an LD₅₀ of 0.03 milligrams per kilogram in monkeys.

Fentanyl was first synthesized by Dr. [Paul Janssen](#) in 1960^[9] following the medical inception of pethidine several years earlier. Janssen developed fentanyl by assaying analogues of the structurally-related drug pethidine for opioid activity.^[10] The widespread use of fentanyl triggered the production of fentanyl citrate (the salt formed by combining fentanyl and citric acid in a 1:1 stoichiometry),^[11] which entered the clinical practice as a general anaesthetic under the trade name Sublimaze in the 1960s. Following this, many other fentanyl analogues were developed and introduced into the medical practice, including [sufentanil](#), [alfentanil](#), [remifentanil](#), and [lofentanil](#).

In the mid 1990s, fentanyl saw its first widespread palliative use with the clinical introduction of the [Duragesic](#) patch, followed in the next decade by the introduction of the first quick-acting prescription formations of fentanyl for personal use, the [Actiq](#) lollipop and [Fentora](#) buccal tablets. Through the delivery method of [transdermal patches](#), fentanyl is currently the most widely used synthetic opioid in clinical practice, with several new delivery methods currently in development.^[12]

Contents

[\[hide\]](#)

- [1 History](#)
- [2 Mechanism of action](#)
- [3 Chemistry](#)
 - [3.1 Synthesis](#)
 - [3.2 Analogues](#)
- [4 Therapeutic use](#)
 - [4.1 Adverse effects](#)
- [5 Illicit use](#)
- [6 Military use](#)
- [7 Overdoses, recalls, and legal action](#)
- [8 References](#)
- [9 External links](#)

History

Fentanyl was first synthesized by Paul Janssen under the label of his relatively newly formed [Janssen Pharmaceutica](#) in 1959. In the 1960s, fentanyl was introduced as an intravenous anesthetic under the trade name of Sublimaze.^[citation needed] In the mid-1990s, Janssen Pharmaceutica developed and introduced into clinical trials the Duragesic patch, which is a formation of an inert alcohol gel infused with select fentanyl doses which are worn to provide constant administration of the opioid over a period of 48 to 72 hours.

After a set of successful clinical trials, Duragesic fentanyl patches were introduced into the medical practice.

Following the patch, a flavored lollipop of fentanyl citrate mixed with inert fillers was introduced under the brand name of Actiq, becoming the first quick-acting formation of fentanyl for use with chronic [breakthrough pain](#). More recently, fentanyl has been developed into an effervescent tab for [buccal](#) absorption much like the Actiq lollipop, followed by a buccal spray device for fast-acting relief and other delivery methods currently in development.

A new fentanyl product has been approved by the FDA for breakthrough cancer pain called Onsolis. It uses a new drug delivery technology called BEMA (fentanyl buccal soluble film) which is placed in the mouth on a small disc. There appears to be less abuse potential because the drug can not be crushed up and snorted like other fentanyl products.

Mechanism of action

Fentanyl provides most of its effects typical of other opioids (especially analgesia, [euphoria](#), and [respiratory depression](#)) through its agonism of the μ -opioid receptors. Its strong potency in relation to that of morphine is largely due to its high [lipophilicity](#). Because of this, it can more easily penetrate the [CNS](#).^[13]

Chemistry

Synthesis

The synthesis of fentanyl ([N-phenyl-N-\(1-phenethyl-4-piperidinyl\)propanamide](#)) by [Janssen Pharmaceutica](#) was achieved in four steps, starting from [4-piperidinone](#) hydrochloride. The 4-piperidinone hydrochloride was first reacted with [2-phenylethylbromide](#) to give [N-phenethyl-4-piperidinone](#) (NPP). Treatment of the NPP intermediate with [aniline](#) followed by reduction with [sodium borohydride](#) affording 4-anilino-N-phenethyl-piperidine (ANPP). Finally ANPP and [propionic anhydride](#) are reacted to form the amide product.

Analogues

The pharmaceutical industry has developed several analogues of fentanyl:

- [Alfentanil](#) (trade name **Alfenta**), an ultra-short-acting (five to 10 minute) analgesic.
- [Sufentanil](#) (trade name **Sufenta**), a potent analgesic (five to 10 times more potent than fentanyl) for use in specific surgeries and surgery in heavily opioid-tolerant/opioid-dependent patients. Its binding affinity is high enough to theoretically break through a [buprenorphine](#) blockade to offer pain relief from acute trauma in patients who are taking high-dose buprenorphine.
- [Remifentanyl](#) (trade name **Ultiva**), currently the shortest-acting opioid, has the benefit of rapid offset, even after prolonged infusions.
- [Carfentanil](#) (trade name **Wildnil**) is an analogue of fentanyl with an analgesic potency 10,000 times that of morphine and is used in veterinary practice to immobilize certain large animals such as elephants.
- [Lofentanil](#) is an analogue of fentanyl with a potency slightly greater than carfentanil.

A number of other fentanyl analogues exist which are classified in the USA as [Schedule I drugs](#), meaning that they have "no currently accepted medical use".^[14] Many of these drugs have been sold on the street as "China White".^[15] These drugs include:

- [3-Methylfentanyl](#) (thought to be the active constituent of [Kolokol-1](#), a [chemical weapon](#))
- [3-Methylthiofentanyl](#)
- [Acetyl- \$\alpha\$ -methylfentanyl](#)
- [\$\alpha\$ -methylfentanyl](#) (see below)
- [\$\alpha\$ -methylthiofentanyl](#)
- [\$\beta\$ -hydroxy-3-methylfentanyl](#)
- [\$\beta\$ -hydroxyfentanyl](#)
- [p-fluorofentanyl](#)
- [Thiofentanyl](#)^[15]

Therapeutic use

Intravenous fentanyl is extensively used for [anesthesia](#) and [analgesia](#), most often in operating rooms and intensive care units. It is often administered in combination with a [benzodiazepine](#), such as [midazolam](#), to produce procedural sedation for endoscopy, cardiac catheterization, oral surgery, etc. Additionally, fentanyl is often used in [cancer therapy](#) and other chronic [pain management](#) due to its effectiveness in relieving pain.



Fentanyl Transdermal System patch (50 $\mu\text{g}/\text{h}$).

It has also been found to be useful to improve the actions of local anesthetic during root canal treatment. According to E.A. Elsharawy in the Journal of Pain Symptom Management (33; 203-207, 2007), the intraligamentary injection of 0.4 ml of fentanyl (0.05 mg/ml) was highly effective in reducing pain when used concurrently with local anesthetic for a pulpectomy procedure (where the "hot" nerve is removed). Fentanyl [transdermal patch](#) (Durogesic/Duragesic/Matrifan) is used in chronic pain management. The patches work by releasing fentanyl into body fats, which then slowly release the drug into the bloodstream over 48 to 72 hours, allowing for long-lasting relief from pain. The patches are available in [generic](#) form and are available for lower costs. Fentanyl patches are manufactured in five patch sizes: 12 [micrograms](#)/hour, 25 $\mu\text{g}/\text{h}$, 50 $\mu\text{g}/\text{h}$, 75 $\mu\text{g}/\text{h}$, and 100 $\mu\text{g}/\text{h}$. Dosage is based on the size of the patch, since the transdermal absorption rate is generally constant at a constant skin temperature. Rate of absorption is dependent on a number of factors. Body temperature, skin type, amount of body fat, and placement of the patch can have major effects. The different delivery systems used by different makers will also affect individual rates of absorption. The typical patch will take effect under normal circumstances usually within 8–12 hours, thus fentanyl patches are often prescribed with another opiate (such as morphine or [oxycodone](#)) to handle breakthrough pain.

Fentanyl lozenges ([Actiq](#)) are a solid formulation of fentanyl citrate on a [stick](#) in the form of a lollipop that dissolves slowly in the mouth for transmucosal absorption. These lozenges are intended for opioid-tolerant individuals and are effective in treating [breakthrough](#) cancer pain. It is also useful for breakthrough pain for those suffering bone injuries, severe back pain, neuropathy, arthritis, and some other examples of chronic nonmalignant pain. The unit is a berry-flavored lozenge on a stick which is swabbed on the mucosal surfaces inside the mouth—inside of the cheeks, under and on the tongue and gums—to release the fentanyl quickly into the system. It is most effective when the lozenge is consumed in 15 minutes. The drug is less effective if swallowed, as despite good absorbance from the small intestine there is extensive first-pass metabolism, leading to an oral bioavailability of 33%. Fentanyl lozenges are available in six dosages, from 200 to 1600 μg in 200 μg increments (excluding 1000 μg and 1400 μg). These are now available in the United States in generic form,^[16] through an [FTC](#) consent agreement.^[17] However, most patients find it takes 10–15 minutes to use all of one lozenge, and those with a dry mouth cannot use this route. In addition, nurses are unable to document how much of a lozenge has been used by a patient, making drug records inaccurate.

Over 2008-09, a wide range of fentanyl preparations became available, including buccal tablets or patches, nasal sprays, inhalers and active transdermal patches (heat or electrical). High-quality evidence for their superiority over existing preparations is currently lacking. Some preparations such as nasal sprays and inhalers may result in a rapid response, but the fast onset of high blood levels may compromise safety (see below). In addition, the expense of some of these appliances may greatly reduce their cost-effectiveness.

On July 16, 2009 the FDA approved Onsolis (BEMA Fentanyl) for breakthrough cancer pain. Onsolis incorporates "bioerodible mucoadhesive" technology, a small soluble film that contains fentanyl which is placed on the inside cheek of the mouth.

In [palliative care](#), transdermal fentanyl has a definite, but limited, role for:

- Patients already stabilized on other opioids who have persistent swallowing problem and cannot tolerate other parenteral routes such as subcutaneous administration.
- Patients with moderate to severe [renal failure](#).
- Troublesome adverse effects on morphine, [hydromorphone](#) or oxycodone.

Fentanyl is sometimes given intrathecally as part of [spinal anesthesia](#) or epidurally for [epidural anesthesia](#) and [analgesia](#). Because of fentanyl's high lipid solubility, its effects are more localized than morphine and some clinicians prefer to use the morphine to get a wider spread of analgesia.

Adverse effects

Fentanyl's major side effects (more than 10% of patients) include diarrhea, nausea, constipation, dry mouth, somnolence, confusion, [asthenia](#) (weakness), and sweating and, less frequently (3 to 10% of patients), abdominal pain, headache, fatigue, anorexia and weight loss, dizziness, nervousness, hallucinations, anxiety, depression, flu-like symptoms, [dyspepsia](#) (indigestion), [dyspnea](#) (shortness of breath), [hypoventilation](#), [apnea](#), and urinary retention. Fentanyl use has also been associated with [aphasia](#).^[18] Despite being a more potent analgesic, fentanyl tends to induce less nausea, as well as less [histamine](#)-mediated itching, in relation to morphine.^[13]

The fentanyl patch has been associated with altered mental state leading to aggression in an anecdotal case report.^[19]

Like other lipid-soluble drugs, the pharmacodynamics of fentanyl are poorly understood. The manufacturers acknowledge there is no data on the pharmacodynamics of fentanyl in elderly, [cachectic](#) or debilitated patients, frequently the type of patient for whom transdermal fentanyl is being used. This may explain the increasing number of reports of [respiratory depression](#) events since the late 1970s.^{[20][21][22][23][24][25][26]} In 2006 the [U.S. Food and Drug Administration](#) began investigating several respiratory deaths, but doctors in the United Kingdom had to wait until September 2008 before being warned of the risks with fentanyl.^[27]

The precise reason for sudden respiratory depression is unclear, but there are several hypotheses:

- Saturation of the body fat compartment in patients with rapid and profound body fat loss (patients with cancer, cardiac or infection-induced [cachexia](#) can lose 80% of their body fat).
- Early carbon dioxide retention causing cutaneous vasodilatation (releasing more fentanyl), together with acidosis which reduces protein binding of fentanyl, releasing yet more fentanyl.
- Reduced sedation, losing a useful early warning sign of opioid toxicity and resulting in levels closer to respiratory depressant levels.

Fentanyl has a [therapeutic index](#) of 270.^[28]

Illicit use



Fentanyl powder seized by a [Lake County](#) Deputy Sheriff in [Painesville, Ohio](#), where a male subject had been discovered unresponsive and struggling to breathe.^[29]

[Illicit use](#) of pharmaceutical fentanyls first appeared in the mid-1970s in the medical community and continues in the present. United States authorities classify fentanyl as a [narcotic](#). To date, more than 12 different analogues of fentanyl have been produced [clandestinely](#) and identified in the U.S. drug traffic. The biological effects of the fentanyls are similar to those of [heroin](#), with the exception that many users report a noticeably less euphoric "high" associated with the drug and stronger sedative and analgesic effects.^{[[citation needed](#)]}

The use of fentanyl has caused death. Because the effects of fentanyl last for only a very short time, regular users may become addicted very quickly.^{[[citation needed](#)]} Additionally, fentanyl may be hundreds of times more potent than street heroin, and tends to produce significantly worse [respiratory depression](#), making it somewhat more dangerous than heroin to users. Fentanyl is most commonly used orally, but like heroin, can also be smoked, snorted or injected. Fentanyl is sometimes sold as heroin, often leading to overdoses. Many fentanyl overdoses are initially classified as heroin overdoses.^{[[30](#)]}

Fentanyl is normally sold on the black market in the form of transdermal fentanyl patches such as [Duragesic](#), diverted from legitimate medical supplies. The patches may be cut up and eaten, or the gel from inside the patch smoked. To prevent the removal of the fentanyl base, [Janssen-Cilag](#), the inventor of the Fentanyl patch, designed the Durogesic patch. The Durogesic patches contain their fentanyl throughout the plastic matrix instead of gel incorporated into a reservoir on the patch. Manufacturers such as [Mylan](#) and [Sandoz](#) have also produced Durogesic-style fentanyl patches that contain the chemical in a silicone matrix, preventing the removal of the fentanyl-containing gel present in other products. The plastic matrix makes the patches far less suitable to transbuccal use and far more difficult to use illicitly than its gel-filled counterpart.^{[[31](#)]}

Another dosage form of fentanyl that has appeared on the streets are the Actiq fentanyl lollipops, which are sold under the street name of "percipop". The pharmacy retail price ranges from US\$10 to US\$30 per unit (based on strength of lozenge), with the black market cost anywhere from US\$15 to US\$40 per unit, depending on the strength.

Non-medical use of fentanyl by individuals without opiate tolerance can be very dangerous and has resulted in numerous deaths.^{[[32](#)]} Even those with opiate tolerances are at high risk for overdoses. Once the fentanyl is in the user's system it is extremely difficult to stop its course because of the nature of absorption. Illicitly synthesized fentanyl powder has also appeared on the United States market. Because of the extremely high strength of pure fentanyl powder, it is very difficult to dilute appropriately, and often the resulting mixture may be far too strong and, consequently, very dangerous.

Some heroin dealers mix fentanyl powder with heroin to increase potency or compensate for low-quality heroin. In 2006, illegally manufactured, non-pharmaceutical fentanyl often mixed with [cocaine](#) or [heroin](#) caused an outbreak of overdose deaths in the United States, heavily concentrated in the cities of [Chicago](#), [Detroit](#), and [Philadelphia](#).^{[[33](#)]} [Baltimore](#), [Pittsburgh](#), [St. Louis](#), [Milwaukee](#), [Camden, New Jersey](#),^{[[34](#)]} [Little Rock](#), and [Dallas](#)^{[[35](#)]} were also affected. The mixture of fentanyl and heroin is known as "magic" or "the bomb," among other names, on the street.^{[[36](#)]}

Several large quantities of illicitly produced fentanyl have been seized by U.S. law enforcement agencies. In June 2006, 945 grams of 83% pure fentanyl powder was seized by [Border Patrol](#) agents in California from a vehicle which had entered from Mexico.^{[[37](#)]} Mexico is the source of much of the illicit fentanyl for sale in the U.S. However, in April 2006 there was one domestic fentanyl lab discovered by law enforcement in [Azusa, California](#). The lab was a source of counterfeit 80-mg [OxyContin](#) tablets containing fentanyl instead of oxycodone, as well as bulk fentanyl and other drugs.^{[[38](#)][[39](#)]}

The "China White" form of fentanyl refers to any of a number of clandestinely produced analogues, especially [α-methylfentanyl](#) (AMF).^{[[40](#)]} This Department of Justice document lists "China White" as a synonym for a number of fentanyl analogues, including 3-methylfentanyl and α-methylfentanyl,^{[[41](#)]} which today are classified as [Schedule I drugs](#) in the United States.^{[[15](#)]} Part of the motivation for AMF is that despite the extra difficulty from a synthetic standpoint, the resultant drug is relatively more resistant to metabolic degradation. This results in a drug with an increased duration.^{[[42](#)]}

Military use

A derivative of fentanyl may have been used as the [Moscow hostage crisis chemical agent](#).^{[[43](#)]}

The [Danish Army](#) is also using the fentanyl stick in military operations as a pain killer. In the documentary film "Armadillo" (2010), a medic mentions the actual use of fentanyl on a severely wounded Danish soldier in Afghanistan.^{[[citation needed](#)]}

[United States Air Force Pararescue](#) uses lollipops with fentanyl.^{[[44](#)]}

[Mossad](#) agents used levofentanyl in their 1997 attempt to kill [Hamas](#) leader [Khalid Mishal](#).^[45]

Overdoses, recalls, and legal action

A number of fatal fentanyl overdoses have been directly tied to the drug over the past several years. In particular, manufacturers of time-release fentanyl patches have come under scrutiny for defective products. While the fentanyl contained in the patches was safe, a malfunction of the patches caused an excessive amount of fentanyl to leak and become absorbed by patients, resulting in life-threatening side effects and even death.^{[46][47]}

Manufacturers of fentanyl transdermal pain patches have voluntarily recalled numerous lots of their patches, and the [U.S. Food and Drug Administration](#) (FDA) has issued public health advisories related to fentanyl patch dangers. Manufacturers affected include Janssen Pharmaceutica Products, L.P.; Alza Corporation; Actavis South Atlantic, LLC; Sandoz; and Cephalon, Inc.^[48]

On May 24, 2009, [Wilco's](#) former guitarist [Jay Bennett](#) died in his sleep of an overdose of the drug via Duragesic time-release patches, which he was prescribed.^[49]

In 2010, [Slipknot's](#) bassist [Paul Gray](#) died after accidentally overdosing on a mixture of fentanyl and morphine, after struggling with substance abuse problems for many years.^[50]

An inquest jury found by a majority verdict of 3-2 that an overdose of fentanyl was responsible for the [death by misadventure](#) of [Anita Chan Lai-ling](#), 69, who died on October 17, 2007, after she was given an overdose of the powerful fentanyl.^[51]

References

1. [^] ["Journal Article"](#). SpringerLink.
<http://www.springerlink.com/content/rr47429177364046/>. Retrieved 2010-07-28.
2. [^] ["Sublimaze Official FDA information, side effects and uses"](#). Drugs.com.
<http://www.drugs.com/pro/sublimaze.html>. Retrieved 2010-07-28.
3. [^] ["Introducing Onsolis"](#). Onsolis.com. <http://www.onsolis.com>. Retrieved 2010-07-28.
4. [^] ["London, 23 April 2009"](#) (PDF).
http://www.emea.europa.eu/pdfs/human/opinion/Instanlyl_6503109en.pdf. Retrieved 2010-07-28.
5. [^] ["Abstral: Prescribing Information"](#). <http://newdrugreview.com/index.php/analgesic-drugs/abstral-fentanyl>. Retrieved 2011-01-07.
6. [^] ["WCPI Focus on Pain Series: The Three Faces of Fentanyl"](#). Aspi.wisc.edu.
<http://aspi.wisc.edu/wpi/focus/spring96.htm>. Retrieved 2010-07-28.
7. [^] [onlinelawyerssource.com](#) [Fentanyl I.V.](#). Retrieved December 23, 2010.
8. [^] ^a ^b ["DBL FENTANYL INJECTION"](#). Medsafe.
<http://www.medsafe.govt.nz/profs/Datasheet/f/FentanylcitrateinjUSP.htm>. Retrieved 2010-07-28.
9. [^] Stanley TH. (1992). "The history and development of the fentanyl series.". *J Pain Symptom Manage*. **7** (3): S3–7. doi:10.1016/0885-3924(92)90047-L. PMID 1517629.
10. [^] Sir James Black (2005). "A Personal Perspective on Dr. Paul Janssen". *J. Med. Chem.* **48** (6): 1687–1688. doi:10.1021/jm040195b. PMID 15771410.
http://www.pauljanssenaward.com/janssen/A_Personal_Perspective.pdf#zoom=100. Retrieved 2010-07-28.
11. [^] ["DailyMed: About DailyMed"](#). Dailymed.nlm.nih.gov.
<http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=10055>. Retrieved 2010-07-28.
12. [^] ["Long Term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain - Full Text View"](#). ClinicalTrials.gov.
<http://clinicaltrials.gov/ct2/show/NCT00538863>. Retrieved 2010-07-28.
13. [^] ^a ^b Stacey Mayes, PharmD MS, Marcus Ferrone, PharmD BCNSP, 2006. [Fentanyl HCl Patient-Controlled Iontophoretic Transdermal System for Pain: Pharmacology](#) The Annals of Pharmacotherapy
14. [^] 21 U.S.C. § 812(b)(1)(B) (2002).
15. [^] ^a ^b ^c [List of Schedule I Drugs](#). U.S. Department of Justice.
16. [^] [Barr Pharmaceuticals](#) (27 September 2006). ["Barr Launches Generic ACTIQ\(R\) Cancer Pain Management Product"](#). Press release.
<http://www.lifesciencesworld.com/news/view/9520>. Retrieved 30 September 2006.

17. [^ FTC \(9 August 2004\). "With Conditions, FTC Allows Cephalon's Purchase of CIMA, Protecting Competition for Breakthrough Cancer Pain Drugs".](#) Press release. <http://www.ftc.gov/opa/2004/08/cimacephalon.htm>. Retrieved 30 September 2006.
18. [^ "Fentanyl Transdermal Official FDA information, side effects and uses".](#) Drugs.com. <http://www.drugs.com/pro/fentanyl-transdermal.html#A02A9CB6-35CF-4F01-A980-C3733E0F861A>. Retrieved 2010-07-28.
19. [^ "European Psychiatry : Fentanyl patch and attempted murder: A case report".](#) ScienceDirect. 2008-03-28. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VM1-4S56Y2F-1NR&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=39b136f64677460556bdbb1be8ed7a90. Retrieved 2010-07-28.
20. [^ Smydo J.](#) Delayed respiratory depression with fentanyl. *Anesthesia Progress*. 26(2):47-8, 1979
21. [^ van Leeuwen L. Deen L. Helmers JH.](#) A comparison of alfentanil and fentanyl in short operations with special reference to their duration of action and postoperative respiratory depression. *Anaesthesist*. 30(8):397-9, 1981
22. [^ Brown DL.](#) Postoperative analgesia following thoracotomy. Danger of delayed respiratory depression. *Chest*. 88(5):779-80, 1985.
23. [^ Bulow HH. Linnemann M. Berg H. Lang-Jensen T. LaCour S. Jonsson T.](#) Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl. *Acta Anaesthesiologica Scandinavica*, 1995; 39(6): 835-9.
24. [^ Nilsson C. Rosberg B.](#) Recurrence of respiratory depression following neurolept analgesia. *Acta Anaesthesiologica Scandinavica*. 26(3):240-1, 1982
25. [^ McLoughlin R. McQuillan R.](#) Transdermal fentanyl and respiratory depression. *Palliative Medicine*, 1997; 11(5):419.
26. [^ Regnard C, Pelham A.](#) Severe respiratory depression and sedation with transdermal fentanyl: four case studies. *Palliative Medicine*, 2003; 17: 714-716.
27. [^ Drug Safety Update, vol 2\(2\) September 2008 p2.](#) Available online on <http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON025631>
28. [^ Stanley, Theodore Henry; Petty, William Clayton \(1983-03-31\). *New Anesthetic Agents, Devices, and Monitoring Techniques*. Springer. ISBN 9789024727964.](#) <http://books.google.com/?id=msYvkdGM6F0C&pg=PA122&lpg=PA122&dq=fentanyl+%22therapeutic+index%22+-narrow+-carfentanil>. Retrieved 20 October 2007.
29. [^ "DEA Microgram Bulletin, June 2006".](#) US Drug Enforcement Administration, Office of Forensic Sciences Washington, D.C. 20537. June 2006. <http://www.usdoj.gov/dea/programs/forensicsci/microgram/mg0606/mg0606.html>. Retrieved 22 June 2009.
30. [^ Boddiger, D. \(2006, August 12\). *Fentanyl-laced street drugs "kill hundreds"*. The Lancet.](#) Retrieved June 15, 2010.
31. [^ "Declaration of Gordon Flynn, Ph.D." \(pdf\).](#) 2004-12-22. <http://www.fda.gov/OHRMS/DOCKETS/dockets/04p0506/04p-0506-c000001-06-Tab-04-Flynn-vol1.pdf>. Retrieved 2010-07-28.
32. [^ \[http://www.deadiversion.usdoj.gov/drugs_concern/fentanyl.htm\]\(http://www.deadiversion.usdoj.gov/drugs_concern/fentanyl.htm\)](#)
33. [^ "CDC MMWR Nonpharmaceutical Fentanyl-Related Deaths - Multiple States, April 2005-March 2007".](#) Cdc.gov. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5729a1.htm>. Retrieved 2010-07-28.
34. [^ \[Press Release by the Chicago Police Department\]\(#\)](#) Police report about a death linked to heroin/fentanyl mixture August 24, 2006
35. [^ "SMU student's death blamed on rare drug".](#) Dallasnews.com. 2006-12-20. <http://www.dallasnews.com/sharedcontent/dws/dn/latestnews/stories/122106dnmetmudrug.2b395050.html>. Retrieved 2010-07-28.
36. [^ \[Fentanyl probe nets 3 suspects\]\(#\)](#) by Norman Sinclair and Ronald J. Hansen, The Detroit News, June 23, 2006. Retrieved June 25, 2006.

37. [^ INTELLIGENCE ALERT: HIGH PURITY FENTANYL SEIZED NEAR WESTMORELAND, CALIFORNIA](#), DEA Microgram, June 2006
38. [^ INTELLIGENCE ALERT: LARGE FENTANYL / MDA / TMA LABORATORY IN AZUZA, CALIFORNIA - POSSIBLY THE "OC-80" TABLET SOURCE](#), DEA Microgram, April 2006.
39. [^ INTELLIGENCE ALERT: OXYCONTIN MIMIC TABLETS \(CONTAINING FENTANYL\) NEAR ATLANTIC, IOWA](#), DEA Microgram, January 2006.
40. [^ List of Schedule I Drugs, U.S. Department of Justice.](#)^[*dead link*]
41. [^ Behind the Identification of China White](#) Analytical Chemistry, 53(12), 1379A-1386A (1981)
42. [^ Van Bever W, Niemegeers C, Janssen P \(1974\). "Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-\(3-methyl-1-\(2-phenylethyl\)-4-piperidyl\)-N-phenylpropanamide and N-\(3-methyl-1-\(1-methyl-2-phenylethyl\)-4-piperidyl\)-N-phenylpropanamide". *J Med Chem* 17 \(10\): 1047–51. doi:10.1021/jm00256a003. PMID 4420811.](#)
43. [^ "Russia names Moscow siege gas". CNN. 2002-10-30. http://archives.cnn.com/2002/WORLD/europe/10/30/moscow.gas/index.html.](#)
44. [^ Shachtman, Noah \(September 10, 2009\). "Airborne EMTs Shave Seconds to Save Lives in Afghanistan". Wired.com. http://www.wired.com/dangerroom/2009/09/airborne_emts_in_astan/. Retrieved July 1, 2010.](#)
45. [^ McGeough, Paul \(2009\) Kill Khalid - The Failed Mossad Assassination of Khalid Mishal and the Rise of Hamas. Quartet Books. ISBN 978-0-7043-7157-6. Page 184.](#)
46. [^ Shapiro, Rick \(5 November 2008\). "Fentanyl Patch Drug Associated with Overdoses & Death Claims". InjuryBoard.com. http://virginiabeach.injuryboard.com/defective-and-dangerous-products/fentanyl-patch-drug-associated-with-overdoses-death-claims.aspx?googleid=250866. Retrieved 31 August 2009.](#)
47. [^ "Fentanyl Pain Patch Fatal Overdose Risk Causes Watson Patch Recall". BagolieFriedman.com. 13 August 2009. http://www.bagoliefriedman.com/news_item.asp?NewsID=495. Retrieved 31 August 2009.](#)
48. [^ "Fentanyl Transdermal System \(marketed as Duragesic and generics\)". Postmarket Drug Safety Information for Patients and Providers. FDA. 30 April 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084307.htm. Retrieved 31 August 2009.](#)
49. [^ "Coroner: Painkiller killed ex-Wilco member". Chicago Tribune. 2009-06-23. http://www.chicagobreakingnews.com/2009/06/coroner-painkiller-killed-ex-wilco-member.html. Retrieved 2010-08-20.](#)
50. [^ "Slipknot bassist Paul Gray died of morphine overdose". BBC News. 2010-06-21. http://news.bbc.co.uk/1/hi/entertainment_and_arts/10372085.stm. Retrieved 2010-07-28.](#)
51. [^ "Son vows to sue on painkiller death". 2010-12-03. http://www.thestandard.com.hk/news_detail.asp?we_cat=4&art_id=105633&sid=30502027&contype=1&d_str=20101203&fc=7. Retrieved 2010-12-03.](#)

External links

- [National Institute of Health \(NIH\) Medline Plus: Fentanyl Buccal \(Transmucosal\)](#)
- [RxList: Fentanyl](#)
- [FDA Public Health Advisory: Fentanyl](#)
- [US DEA information: fentanyl](#)
- [08/16/2007 News Release: Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain](#)
- [Description of use of Fentanyl in Russia as an incapacitating weapon. See also Moscow theater hostage crisis](#)
- [BBC news report on Russian siege story](#)
- [Lancaster Online story - New Killer: Fentanyl-Heroin Mix](#)
- [Fentanyl: Emergency Response Database](#). National Institute for Occupational Safety and Health.
- [U.S. National Library of Medicine: Drug Information Portal - Fentanyl](#)